新闻公告

临床试验取得显著进展:CBT-009和CBT-004
Cloudbreak Pharma(拨康视云)欣然宣布 1. 用于治疗青少年近视的新药CBT-009 已和美国达成进入临床III期的协议 2. 用于治疗充血性结膜黄斑的新药CBT-004在美国递交临床II期申请
10月 11, 2023

Abu Abraham, M.D.’s appointment as Chief Medical Officer
We are pleased to announce that Abu Abraham, M.D. has joined as the group’s Chief Medical Officer. Dr. Abu Abraham has over 20
6月 26, 2022